Seemingly small research funding cuts could hinder progress in nanotechnology

Public release date: 8-Apr-2013 [ | E-mail | Share ]

Contact: Michael Bernstein m_bernstein@acs.org 504-670-4707 (New Orleans Press Center, April 5-10) 202-872-6042

Michael Woods m_woods@acs.org 504-670-4707 (New Orleans Press Center, April 5-10) 202-872-6293

American Chemical Society

NEW ORLEANS, April 8, 2013 Cuts in federal funding of nanotechnology research threaten to slow progress toward some of the field's greatest promises, including commercialization of sustainable new energy sources that do not contribute to global warming, an international authority in the field cautioned here today.

Speaking at the 245th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society, A. Paul Alivisatos, Ph.D., expressed concern that the cuts come when nanotechnology is poised to deliver on those promises. He told the meeting, which continues through Thursday, that ill-conceived cuts could set back America's progress in nanotechnology by decades.

"The National Science Foundation announced that they will issue a thousand fewer new grants this year because of sequestration," said Alivisatos, referring to the across-the-board mandatory federal budget cuts that took effect on March 1. "What it means in practice is that an entire generation of early career scientists, some of our brightest and most promising scientists, will not have the funding to launch their careers and begin research properly, in the pathway that has established the United States as leader in nanotechnology research. It will be a setback, perhaps quite serious, for our international competitiveness in this key field."

Alivisatos described applications of nanotechnology that can help reduce fossil fuel consumption and the accompanying emissions of carbon dioxide, the main greenhouse gas. He is professor of chemistry and materials science and the Larry and Diane Bock Professor of Nanotechnology at the University of California at Berkeley, director of the Lawrence Berkeley National Laboratory and co-editor of the ACS journal Nano Letters. Nanoparticles of various substances already have been incorporated into solar panels, rechargeable batteries and other clean-energy solutions. These particles are so small that 1,000 to 100,000 could fit across the width of a human hair. When size diminishes to that scale, gold, silver, copper and other substances take on physical properties vastly different from lumps of bulk material.

Although nanotechnology remains a science in its infancy, it already has had a major impact on many other industrial segments, ranging from consumer products to national security and defense. By one estimate, more than 600 nanotechnology-enabled consumer products already are on the market, including mobile phones, cosmetics, music systems and clothing. Forecasts suggest that the global market for such products will increase by more than 10 percent annually in the years ahead.

Alivisatos expressed concern, however, that cuts in federal funding will take a heavy toll on the still-emerging field. He explained that the reductions stand to affect scientists at almost every stage of making contributions to society. Young scientists, for instance, will find it more difficult to launch research programs in new and promising fields. Established scientists will have to trim research programs, and may not have the money to explore promising new leads.

Continued here:

Seemingly small research funding cuts could hinder progress in nanotechnology

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market

NOKOMIS, Fla.--(BUSINESS WIRE)--

As Rainbow Coral Corp.s (RBCC) biotech subsidiary, Rainbow BioSciences, seeks out potentially lucrative new opportunities in the $232 billion personalized medicine market, the company announced today that it will target new innovations in the growing field of companion diagnostics.

The personalized medicine market in the U.S. is ripe for expansion, with PricewaterhouseCoopers predicting that the sector could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, which could grow to as large as $42 billion by 2015, according to industry analysts TriMarkPublications.com.

The key to that growth will be innovation. Companion diagnostics is the use of genetic variation to chart different patient responses to specific drugs or biologic agents in order to create effective, efficient treatments tailored to a patients genetic profile. The emerging field is believed by many medical experts to have an increasingly important role to play in cancer treatments in coming years.

Companion diagnostics represent the very cutting edge of technology in medicine today, said RBCC CEO Patrick Brown. We believe the key to our success is bringing desperately needed new innovations to the market that will improve patient outcomes and reduce healthcare costs. Companion diagnostics offer us the best opportunities to achieve that goal.

For more information on Rainbow BioSciences personalized medicine initiatives, please visitwww.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Continue reading here:

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market

New law bans public smoking in Medicine Hat

A new law set to take effect in Medicine Hat will ban smoking in outdoor public places just in time for summer.

The law, spearheaded by local high school students, restricts smoking within 10 metres of public fields, paths, playgrounds and beaches.

"It's about trying to find that balance where non-smokers' rights can be honoured but also recognizing that smoking isn't illegal," says Varley Weisman, manager of social development with the city of Medicine Hat.

More than 50 municipalities across Canada already have similar bylaws in place, including Edmonton, Grande Prairie and Red Deer. Calgary does not.

"There's nothing worse than inhaling second-hand cigarette smoke, while being active," says Medicine Hat's Youth Advisory Chair Austin Desharnais. "Smokers have the right to smoke but saying that, we feel it's also important that non-smokers have the rights too."

Some say that the new law goes too far.

"I think they should be allowed to smoke," says local resident Logan Krastel. "We're outside like, you know, they have rights too."

Medicine Hat will be putting up signs in the next few weeks and spreading the word about its new rule.

The new law will take effect in the coming months and will carry a $100 fine for infractions.

A motion on smoking in outdoor areas where children are allowed is going to committee in Calgary next month.

Here is the original post:

New law bans public smoking in Medicine Hat

To Get Medicine to Africa, Health Experts Turn to Coca-Cola

Running water, electricity, and paved roads are hard to find in the remotest parts of sub-Saharan Africa. A bottle of warm Coca-Cola, though? No sweat. This impressive reach isnt lost on public health advocates. They are looking to Cokes distribution network to bring cheap, life-saving medication to some of the worlds most remote places.

Since September, more than 40,000 medicine kits designed to slip between Coke bottles stacked in a case have made the journey deep into the Zambian countryside. Called Kit Yamoyo, the packets were designed by London branding agency pi global for the U.K.-based health charity called ColaLife to fight one of sub-Saharan Africas biggest child killers, diarrhea. The kits, priced at the equivalent of $1, carry vital antidiarrheal medicinea blister pack of zinc pills, oral rehydration saltsin a container that doubles as a mixing vessel. (The kit also carries a thin bar of soap.)

Instead of a mother having to travel three, sometimes four hours to a regional health center, she can now go to the community shop where they usually find Coca-Cola for sale, says Rohit Ramchandani, public health adviser and principal investigator for ColaLife. Our model looks specifically at how we can partner with and leverage private sector distribution channels, these companies that are able to get their product out to that last mile in the most remote parts of the world. In the future, ColaLife plans to use the same container design to transport safe-birthing kits, mosquito nets, and nutrient supplements, Ramchandani says.

Pi globals product designa heat-sealed, water-resistant, tamper-proof plastic kit that looks as if it could hold a wedge-shaped vending machine sandwichallows 10 kits to be slipped inside a single crate of Coca-Cola. In this part of the world, it also represents the first all-in-one, single-dose antidiarrheal kit.

Cokes involvement in the project has been easier to measure in crates than in dollars. We didnt ask Coca-Cola and their bottler SABMiller to fund the Zambia trial directly, says Jane Berry, ColaLifes business development director. We wanted it to be independentcreating evidence and learning [that] people could trust. What we wanted was permission to piggyback on their knowledge, brand, expertise, methods, and networks, which they have very generously given.

Read this article:

To Get Medicine to Africa, Health Experts Turn to Coca-Cola

Research and Markets: European Nuclear Medicine / Radiopharmaceuticals Market – Global Trends & Forecasts to 2017

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecas" report to their offering.

The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the European scenario.

Key Topics Covered:

1 Key Take-Aways

2 Executive Summary

3 Market Overview

Original post:

Research and Markets: European Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecasts to 2017

MBC Guides Family Medicine Practitioners to Effectively Tackle the ACA Impact!

WILMINGTON, Delaware, April 9, 2013 /PRNewswire/ --

With the Family Physicians revenue cycle management in a state of transition due to the upcoming Affordable Care Act (ACA), Medicalbillersandcoders.com has witnessed a large demand from Family Medicine practice centers across the US keen on outsourcing their billing functions to MBC in order to enhance their RCM.

The ACO impact on Family practice billing and coding

The impact Accountable Care Organizations (ACO) will have on these practices explains the reason behind an increased number of Family practices currently rushing to MBC for their billing solutions.

Though the ACO environment may benefit these practices by promoting primary care hence making it accessible and improving provider reimbursements, it also brings with it many changes as it prompts federal and commercial payers to change the way they make payments. The challenge it provides to Family practice billing and coding is that they would require transitioning their reimbursement models from volume-based to value-based to a higher number of patients with little time left for billing.

MBC's billing and coding experts believe that "Family Physicians within the next five years will need to adopt the new revenue reimbursement models as a result of ACA. Though this may seem simple enough, practitioners will need to work much harder to maximize their revenues."

Identifying resulting revenue transition challenges

MBC understands that in the ACO environment accurate medical coding and billing is vital to maximizing revenue, being aware of the resulting issues they face with this transition, -

How MBC has been guiding Family Medicine Practitioners

Medicalbillerandcoders.com is aware that improved Family Practice revenue cycle management requires in-depth, insider industry expertise of the new coding, billing and compliance regulations. MBC specialists continuously correlate higher practice revenue to timely billing and account reimbursements, offering best billing strategies, models and consultancy and providing guidance in areas like population health management.

Originally posted here:

MBC Guides Family Medicine Practitioners to Effectively Tackle the ACA Impact!

Defining the Scope of Skills for Family Medicine Residencies

Newswise BOSTON (April 9, 2013) Medical school graduates entering one family medicine residency program might receive training that is markedly different than another family medicine residency program. While these new medical school graduates, called residents, will gain the clinical knowledge needed to practice medicine, their scope of skills depend on their specific experiences as residents. A team of healthcare professionals from the Family Medicine Residency Program at Tufts University School of Medicine have published a paper in the Journal of Graduate Medical Education that suggests a way to evaluate family medicine residents based on their level of competency.

Family medicine resident training is currently determined by the types of patients that the residents treat at their specific hospital or clinic, rather than being determined by the curriculum. We have created a list of entrustable professional activities or EPAs to assess clinical competencies that clearly define the breadth of skills required at the completion of residency, said Allen Shaughnessy, Pharm.D., M.Med.Ed., professor at Tufts University School of Medicine and fellowship director of the Tufts University Family Medicine Residency Program at Cambridge Health Alliance.

Shaughnessy worked with a team of healthcare professionals from Tufts University School of Medicines Family Medicine Residency Program to develop a list of 76 EPAs around which to structure a competency-based assessment of family medicine residents.

Competence is defined as the ability to do something successfully. Defining the list of somethings in family medicine residencies has been difficult for both educators and regulators, said Gregory L. Sawin, M.D., M.P.H., assistant professor at Tufts University School of Medicine and program director, Tufts Family Medicine Residency at Cambridge Health Alliance.

Competency-based medical education ensures that medical residents acquire a certain set of skills, behaviors, and attitudes in addition to the clinical knowledge needed to practice medicine. When these skills, behaviors, and attitudes are integrated and performed in an educational setting, they become known as entrustable professional activities. An activity is entrustable when a supervisor deems that a medical resident could have performed a task without supervision; in this case, the resident has demonstrated competency in a given area. As an example, the authors write:

For example, a competent family medicine physician is expected to provide care for a child with a respiratory illness. This includes eliciting a history, performing a physical examination, arriving at a diagnosis, and implementing a plan of care that is evidence based and takes into account the needs and values of the patient. Although each of these skills can be separately measured and documented in a variety of settings, the overall performance of them in situ constitutes the entrustable activity.

In addition to confirming that family medicine residents know how to treat a specific disease or condition, the EPAs can ensure that residents acquire skills that enable them to effectively interact with medically-diverse patients, uphold ethical principles, use information sources at the point of care, and develop skills relating to running a medical practice.

The leading effort to define competencies is the Outcome Project, from the Accreditation on Graduate Medical Education (ACGME) and the American Board of Medical Specialties. The Outcome Project is shifting medical education from assuring quality through intense training processes to measuring outcomes and specific skill. This shift in medical training was the result of calls for greater accountability in all aspects of the profession.

Shaughnessy notes that the Outcome Project leaves the definition of actual competencies and their assessment to individual residencies. Interpretation may lead to vague competency categories that are not specific enough to provide definitive guidance to residents or faculty members regarding what learning needs to be accomplished and documented. In response, the EPAs provide a detailed, concrete approach to training and evaluating residents in how they provide care.

The initial EPAs presented in the paper were developed at the Tufts University School of Medicine Family Medicine Residency Program, based on the ACGME guidelines, over a two year period. Twenty-one experts were recruited to further determine and refine the EPAs that are most relevant to family medicine education. The experts participated in two rounds of anonymous, internet-based surveys to compile the final list of EPAs. The process began with 91 EPAs that were then narrowed down to 76 based on the feedback.

Read more from the original source:

Defining the Scope of Skills for Family Medicine Residencies

Boston Children’s Hospital, Harvard Medical School to receive life sciences grants

By Chris Reidy, Globe Staff

The Massachusetts Life Sciences Center, a quasi-public state agency, announced Monday that about $9 million in grants are being allocated to Boston Childrens Hospital and Harvard Medical School to renovate research labs.

Timothy P. Murray. File photo. ( David L Ryan/Globe Staff)

Additional grants ranging from $50,000 to $200,000 have been also set aside for Bunker Hill Community College, Quincy College, and Regis College.

In all, the center said it announced more than $9.35 million in grants to support life-sciences-related capital projects in the Greater Boston area.

The Massachusetts Life Sciences Center is charged with investing $1 billion over a 10-year period to support the growth of the states life sciences industries. The initiative is a priority for the administration of Governor Deval Patrick.

In a statement, Lieutenant Governor Timothy Murray said, This funding is part of the Massachusetts Life Sciences Centers overall efforts to collaborate with academia and the business community to enhance research, workforce training, and job creation in the life sciences.

The $4 million grant awarded to Boston Childrens Hospital will help establish the Childrens Center for Cell Therapy and support lab renovations that will allow additional cell culturing facilities and a robotics area designed to perform highly specialized chemical screening on stem cells, the center said in its press release.

With its $5 million grant, Harvard Medical School seeks to create a Laboratory of Systems Pharmacology that will be a multidisciplinary incubator for providing better clinical trial information in the drug development process, the release said.

Grants were also given to vocational schools and high schools with the goal of furthering access to the so-called STEM subjects of science, technology, engineering, and math. Schools in line to receive grants include Norfolk County Agricultural High School, Quincy High School, and Revere High School, the center said.

Read more here:

Boston Children’s Hospital, Harvard Medical School to receive life sciences grants

Super Dive | Night Dive USAT Liberty Wreck, Tulamben, Bali, Indonesia | 01092012 – Video


Super Dive | Night Dive USAT Liberty Wreck, Tulamben, Bali, Indonesia | 01092012
Super Dive | Night Dive USAT Liberty Wreck, Tulamben, Bali, Indonesia | 01092012 Diver: - Achmad Firdaus Ariyanto - Caca Gabriella - Teddy Agra - Gusman Ojel...

By: SuperDiveIndo

Go here to read the rest:

Super Dive | Night Dive USAT Liberty Wreck, Tulamben, Bali, Indonesia | 01092012 - Video